Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Zentalis Pharmaceuticals, Inc. ZNTL NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$2.00
-61.4%

Zentalis Pharmaceuticals, Inc. (ZNTL) is a Biotechnology company in the Healthcare sector, currently trading at $5.19. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ZNTL = $2 (-61.4% upside).

Valuation: ZNTL trades at a trailing Price-to-Earnings (P/E) of -1.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.09.

Net income is $137M (loss), growing at +12.4%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $40M against $216M equity (Debt-to-Equity (D/E) ratio 0.18, conservative). Current ratio is 6.93 (strong liquidity). Debt-to-assets is 13.7%. Total assets: $289M.

Analyst outlook: 8 / 12 analysts rate ZNTL as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 37/100 (Fail), Income ?/100 (Fail).

$2.00
▼ 61.43% Downside
Average Price Target
The 12-month price target for Zentalis Pharmaceuticals, Inc. is $2.00.

ZNTL SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 63/100
Valuation — P/E, PEG, Forward PEG
GROWTH 48/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 37/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ZNTL

✓
VALUE Pass
63/100
ZNTL trades at a trailing Price-to-Earnings (P/E) of -1.7 (S&P 500 average ~25). Forward PEG 0.09 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $2, implying -61.4% from the current price $5. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
48/100
ZNTL: -100%/yr revenue is, +12.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ZNTL: Debt-to-Equity (D/E) ratio 0.18 (conservative), Current ratio is 6.93 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
ZNTL: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
37/100
Analyst outlook: 8 / 12 analysts rate ZNTL as buy (67%). Analyst consensus target is $2 (-61.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.01-3.95
Volume2.35M
Avg Volume (30D)1.78M
Market Cap$367.85M
Beta (1Y)1.66
Share Statistics
EPS (TTM)-1.91
Shares Outstanding$71.87M
IPO Date2020-04-03
Employees166
CEOJulie Eastland
Financial Highlights & Ratios
Gross Profit$-739K
EBITDA$-145.51M
Net Income$-137.06M
Operating Income$-146.25M
Total Cash$245.89M
Total Debt$39.58M
Net Debt$3.58M
Total Assets$288.97M
Price / Earnings (P/E)-2.7
Analyst Forecast
1Y Price Target$2.00
Target High$2.00
Target Low$2.00
Upside-61.4%
Rating ConsensusBuy
Analysts Covering12
Buy 67% Hold 33% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS98943L1070

Price Chart

Track all markets on TradingView
ZNTL
Zentalis Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.01 52WK RANGE 3.95

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 MRTX
MRTX
Mirati Therapeutics, Inc.
$58.70
-0.17%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 SNDX
SNDX
Syndax Pharmaceuticals, Inc.
$24.43
+0.74%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message